Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. | Aplastic Anemia and MDS International Foundation

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

Journal Title: 
Ann Oncol
Author(s): 
Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M
Primary Author: 
Nösslinger T
Original Publication Date: 
Wednesday, July 15, 2009

BACKGROUND:

The International Prognostic Scoring System (IPSS) is the golden standard to assess prognosis in myelodysplastic syndromes (MDS). The aim of this analysis was to study age and gender as interacting variables for individualized prognostication.

PATIENTS AND METHODS:

In all, 897 patients with primary MDS treated with supportive care only were examined in a retrospective multicenter study. A Cox model was developed to determine the prognostic impact of age and gender on survival and to examine their modulating influence on IPSS results. Based on main effects and interactions of these variables, we established an individualized age- and gender-adapted scoring system to improve prognostication in MDS.

RESULTS:

While the risk of a patient in the IPSS is best represented by the values 0 (low), +1 (intermediate-1), +2 (intermediate-2), and +3 (high), these values were found to vary between -1.9 and +3.5 in the same patients when including age and gender. Whereas in low-risk MDS, male patients were found to have a less favorable survival, a particularly high risk (+3.5) was found in younger (< or = 66 years) high-risk female patients.

CONCLUSION:

The inclusion of age and gender and their respective interactions contribute to improved and individualized prognostication in MDS.

Bone Marrow Diseases: